Try our Advanced Search for more refined results
Merck Sharp & Dohme Corp., Petitioner v. Doris Albrecht, et al.
Case Number:
17-290
Court:
Nature of Suit:
4365 Personal Injury-Product Liability
Firms
- Center for Constitutional Litigation
- Covington & Burling
- Gibbs Law Group
- Gupta Wessler
- Jones Day
- Kellogg Hansen
- Robbins Russell
- Viles & Beckman
- Zuckerman Spaeder
Companies
Sectors & Industries:
-
September 14, 2018
Justices Told FDA's 'Smoking Gun' Sinks Fosamax MDL
Merck Sharp & Dohme Corp. has told the U.S. Supreme Court that "smoking gun" evidence from the U.S. Food and Drug Administration should sink a Third Circuit decision reviving multidistrict litigation over the company's alleged failure to warn about a risk of femoral fractures from its osteoporosis drug Fosamax.
-
July 17, 2018
Product Liability Cases To Watch: Midyear Report
The tsunami of litigation over the nation's deadly opioid crisis will continue to keep attorneys riveted as the parties work toward trial dates next year. And after a string of losses for patients who claim that Bayer failed to warn of its blood thinner Xarelto's bleeding risks, attorneys are looking to see if they can find a winning argument. Here are the product liability cases attorneys will be keeping an eye on for the rest of 2018.
-
June 29, 2018
Merck Fosamax Appeal Faces Uncertain Odds In High Court
On a U.S. Supreme Court with a recent retirement and a recusal, Merck's appeal of a Third Circuit decision reviving multidistrict litigation over the drug company's alleged failure to warn about femoral fracture risk from osteoporosis drug Fosamax could result in a 4-4 tie, experts said.
-
June 28, 2018
Supreme Court Agrees To Review Fosamax MDL Revival
The U.S. Supreme Court on Thursday agreed to consider a Third Circuit decision that revived multidistrict litigation over Merck's alleged failure to warn about a risk of femoral fractures from its osteoporosis drug Fosamax.
-
June 11, 2018
Merck Urges Justices To Review Fosamax MDL Revival
Merck has told the U.S. Supreme Court that a brief by the U.S. solicitor general bolsters its bid to reverse a Third Circuit decision reviving multidistrict litigation over its alleged failure to warn about a risk of femoral fractures from its osteoporosis drug Fosamax.
-
June 06, 2018
Fosamax Users Urge High Court To Turn Down Merck Appeal
Fosamax users on Tuesday urged the U.S. Supreme Court not to hear Merck's appeal of a Third Circuit decision reviving multidistrict litigation over the pharmaceutical giant's alleged failure to warn about its osteoporosis drug, saying that the case doesn't meet the court's usual standard for review.
- ← Previous
- 1
- 2
- Next →